Sigilon Therapeutics' core business segment revolved around cell therapy, utilizing its Shielded Living Therapeutics™ platform. This platform aimed to develop functional cures for chronic diseases by encapsulating allogeneic cells within a biocompatible matrix, protecting them from immune rejection. Research and development efforts focused on optimizing cell encapsulation techniques and enhancing the therapeutic efficacy of encapsulated cells. The company explored various therapeutic areas, including hemophilia A, mucopolysaccharidosis type 1 (MPS-1), Fabry disease, and type 1 diabetes. By delivering continuous and prolonged release of functional enzymes or replacement cells, Sigilon aimed to alleviate disease progression and improve patient outcomes. This segment held significant market potential, offering a novel approach to treating chronic conditions with unmet medical needs.

Sigilon Therapeutics also operated within the regenerative medicine space, focusing on developing cell-based therapies to restore or replace damaged tissues and organs. This segment leveraged the company's expertise in cell encapsulation and biomaterials to create implantable devices that promote tissue regeneration and functional recovery. Research and development activities included exploring novel cell sources, optimizing encapsulation strategies, and evaluating the long-term safety and efficacy of regenerative medicine products. The company targeted various therapeutic applications, including diabetes, where encapsulated islet cells could potentially replace damaged pancreatic cells and restore insulin production. This segment represented a promising avenue for addressing chronic diseases with limited treatment options and improving patient quality of life.